Table A.7b: Longer-Run Treatment Effects (ITT)

Outcome Variable	(1) Horizon (months)	(2) Mean	(3) No Controls	(4) Strata FEs	(5) Post-Lasso
A. Medical Spending [survey]					
Pharmaceutical drug utilization [survey]	24	0.729	0.010	N/A	N/A
			(0.017)	N/A	N/A
			[0.910]	N/A	N/A
		N=3,019	N=3,019	N/A	N/A
Physician/ER utilization [survey]	24	0.765	−0.004	N/A	N/A
			(0.016)	N/A	N/A
			[0.910]	N/A	N/A
		N=3,019	N=3,019	N/A	N/A
Hospital utilization [survey]	24	0.027	0.003	N/A	N/A
			(0.006)	N/A	N/A
			[0.910]	N/A	N/A
		N=3,019	N=3,019	N/A	N/A

Notes: This table replicates Appendix Table A.7b from Jones, Molitor, and Reif (QJE 2019) using public-use data. The Westfall-Young p-values, reported in brackets, do not exactly replicate the values from the original paper due to censoring in the public-use data. N/A indicates a censored value.